Regorafenib

Treatment for Colon and rectum cancer

Typical Dosage: 160 mg orally once daily for 3 weeks, followed by 1 week off, every 4 weeks

Effectiveness
50%
Safety Score
30%
Clinical Trials
10
Participants
7K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
160 mg orally once daily for 3 weeks, followed by 1 week off, every 4 weeks
Time to Effect
2-4 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGH
Number Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$8,000
Side Effect Mgmt:$7,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$400,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$3,900,000
Cost per Remission
$19,500,000
Comparison vs Best Supportive Care
Cost Difference
+$195,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Regorafenib Outcomes

for Colon and rectum cancer

Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+5%
Remission Rate
+1%
Common Side Effects
Hand-foot skin reaction
+60%
Fatigue
+65%
Diarrhea
+35%
Hypertension
+25%
Hepatotoxicity
+12%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
2 active trials recruiting for Regorafenib in Colon and rectum cancer

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

NCT06865521ACTIVE NOT RECRUITINGNA
View Study
22 participants
INTERVENTIONAL
Chengdu, China +1 more
Started: Feb 21, 2025

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

NCT07003022RECRUITINGPHASE2
View Study
40 participants
INTERVENTIONAL
Shanghai, China
Started: Jun 1, 2025
Completed Clinical Trials
5 completed trials for Regorafenib in Colon and rectum cancer

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

NCT04534218COMPLETEDPHASE2
View Study
49 participants
INTERVENTIONAL
Besançon, France +2 more
Started: Oct 16, 2020

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

NCT04362839COMPLETEDPHASE1
View Study
39 participants
INTERVENTIONAL
Duarte, United States
Started: May 27, 2020

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

NCT04126733COMPLETEDPHASE2
View Study
70 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Oct 14, 2019

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

NCT05839951COMPLETED
View Study
818 participants
OBSERVATIONAL
Whippany, United States
Started: Apr 24, 2023

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378COMPLETEDPHASE1
View Study
129 participants
INTERVENTIONAL
Phoenix, United States +8 more
Started: Dec 11, 2017